Complete Custom Recombinant Antibody Development Services
Abzyme’s yeast-based display platform with self-diversifying antibody libraries (single domain camelid VHH and human VH antibodies, full human ScFv and IgG antibodies) can replace the conventional hybridoma antibody development approach, offering comparable antibody quality with additional advantages. Combining the benefits of eukaryotic-based display, in vivo maturation via inducible hypermutation, FACS-based cell sorting and our experienced team, we offer:

• Project design consultation
• Specific, high affinity antibodies applicable to most antigen types, including difficult and non-immunogenic targets
• Single domain antibodies in monovalent and multi-valent, bispecific and multi-specific recombinant formats
• Human ScFV antibodies
• Human Fab and IgG antibodies
• Rabbit monoclonal antibodies
• Optimization of existing antibodies
• Antibody engineering
• Recombinant, endotoxin-free antibody production in different cell systems, including mammalian cells for glycosylated antibodies.
• Cytoflow and SPR-based antibody characterization

Rapid High Quality Antibody Development In Just 8-10 Weeks
Unique to Abzyme is the in vivo maturation platform mimicking mammalian antibody diversification processes and the speed at which we can develop a high affinity and specific recombinant antibody. Central to this speed is the combination of our eukaryotic-based in vitro antibody discovery/optimization platform, yeast display self-diversifying libraries, rapid target-directed antibody maturation, and a FACS-based single cell sorting approach to identify relevant antibodies.

Our naïve, yet highly diversified Abzyme yeast display antibody libraries are further diversified by inducible hypermutation and target affinity-selected. After three diversification/enrichment cycles, single cells expressing high affinity antibodies with desired therapeutic attributes are isolated by two consecutive FACS experiments. If desired additional enrichment and FACS sorting steps can be applied to increase antibody affinity or select for additional activities (e.g. cross-reactivity). Single yeast display antibody clone candidates are further validated by cytoflow analysis using various antigen concentrations to affinity rank order clones. Confirmed clones will be transferred into either E.coli or mammalian expression systems for further analyses (e.g.ELISA) and for production of final antibodies.

Antigen types we process include:

• Peptides
• Protein fragments
• Full-length proteins
• Post-translationally modified peptides and proteins
• “Less or non-immunogenic” antigens
• Cell surface antigens including multi-pass transmembrane proteins
• Small molecules
• Toxins

Abzyme Supporting Services:

• Affinity maturation of existing antibodies
• Antibody optimization
  • scFv to IgG conversion
  • Isotype conversion
  • Hybridoma to recombinant conversion
  • CDR grafting and humanization
• Bispecific antibodies
• Antibody production
• Cytoflow and SPR-based antibody characterization